BaiCheng Pharma (301096.SZ) Forecasts H1 Net Profit of RMB 0-6 Million, Plunging 95.53%-100% YoY

Stock Track07-15

BaiCheng Medicine Technology Co., Ltd. (301096.SZ) has released its preliminary financial estimates for the first half of 2025, projecting a stark downturn in profitability. The company anticipates net profit attributable to shareholders to range between RMB 0 and RMB 6 million, reflecting a precipitous year-over-year decline of 95.53% to 100%.

This dramatic contraction stems from significantly reduced revenue recognition across key pharmaceutical research and development service segments. Concurrently, BaiCheng Pharma expects an adjusted net loss, excluding non-recurring items, of RMB 9 million to RMB 15 million for the same period.

Operational headwinds intensified throughout the reporting cycle, with delayed project milestones and heightened R&D expenditure contributing to the substantial earnings erosion. The pharmaceutical research firm faces mounting pressure to accelerate commercialization pipelines while managing escalating operational costs. Market analysts highlight that this performance signals potential challenges in translating BaiCheng's extensive service portfolio into sustainable profitability amid shifting industry dynamics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113392056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113392056","market":"hk","top_or_hot":-1,"title":"BaiCheng Pharma (301096.SZ) Forecasts H1 Net Profit of RMB 0-6 Million, Plunging 95.53%-100% YoY","media":"Stock Track","content":"<p>BaiCheng Medicine Technology Co., Ltd. (301096.SZ) has released its preliminary financial estimates for the first half of 2025, projecting a stark downturn in profitability. The company anticipates net profit attributable to shareholders to range between RMB 0 and RMB 6 million, reflecting a precipitous year-over-year decline of 95.53% to 100%.</p>\n<p>This dramatic contraction stems from significantly reduced revenue recognition across key pharmaceutical research and development service segments. Concurrently, BaiCheng Pharma expects an adjusted net loss, excluding non-recurring items, of RMB 9 million to RMB 15 million for the same period.</p>\n<p>Operational headwinds intensified throughout the reporting cycle, with delayed project milestones and heightened R&D expenditure contributing to the substantial earnings erosion. The pharmaceutical research firm faces mounting pressure to accelerate commercialization pipelines while managing escalating operational costs. Market analysts highlight that this performance signals potential challenges in translating BaiCheng's extensive service portfolio into sustainable profitability amid shifting industry dynamics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BaiCheng Pharma (301096.SZ) Forecasts H1 Net Profit of RMB 0-6 Million, Plunging 95.53%-100% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiCheng Pharma (301096.SZ) Forecasts H1 Net Profit of RMB 0-6 Million, Plunging 95.53%-100% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-15 20:58 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BaiCheng Medicine Technology Co., Ltd. (301096.SZ) has released its preliminary financial estimates for the first half of 2025, projecting a stark downturn in profitability. The company anticipates ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301096","symbol_name":"百诚医药","start_time":0,"source_url":"","article_id":"1113392056","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113392056","pubTimestamp":1752584305,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":null,"summary":"BaiCheng Medicine Technology Co., Ltd. (301096.SZ) has released its preliminary financial estimates for the first half of 2025, projecting a stark downturn in profitability. The company anticipates...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"301096":"百诚医药","BK0216":"研究试验"},"translate_title":"百诚医药(301096.SZ)预告H1净利0-600万同比暴跌95.53%-100%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301096":1},"content_text":"BaiCheng Medicine Technology Co., Ltd. (301096.SZ) has released its preliminary financial estimates for the first half of 2025, projecting a stark downturn in profitability. The company anticipates net profit attributable to shareholders to range between RMB 0 and RMB 6 million, reflecting a precipitous year-over-year decline of 95.53% to 100%.\nThis dramatic contraction stems from significantly reduced revenue recognition across key pharmaceutical research and development service segments. Concurrently, BaiCheng Pharma expects an adjusted net loss, excluding non-recurring items, of RMB 9 million to RMB 15 million for the same period.\nOperational headwinds intensified throughout the reporting cycle, with delayed project milestones and heightened R&D expenditure contributing to the substantial earnings erosion. The pharmaceutical research firm faces mounting pressure to accelerate commercialization pipelines while managing escalating operational costs. Market analysts highlight that this performance signals potential challenges in translating BaiCheng's extensive service portfolio into sustainable profitability amid shifting industry dynamics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113392056","isCrawlerRequest":true}